Our news journalists obtained a quote from the research from University Hospital, "Two fractures had already occurred in pagetic (right tibia) and non pagetic bones (right fibula) within the last 2 years, and she presented rib fractures, another right tibia fracture and right femur fracture during hospitalization time. X-rays films showed major osteolysis of left ulna and right tibia. Blood samples and technetium bone scan brought no evidence for sarcoma or lytic evolution of the disease. A transiliac bone biopsy on non pagetic bone site confirmed the diagnosis of osteomalacia (increased osteoid parameters), with secondary hyperparathyroidism (hook resorption). In Paget's disease of bone, continuous treatment by etidronate may induce generalized osteomalacia, and increase the risk of fracture in both pagetic and non-pagetic bones."
According to the news editors, the research concluded: "Whereas physicians and pharmaceutical industry try to improve the observance of those drugs, this striking observation also points out that a prescription always needs to be updated."
For more information on this research see: Osteomalacia in a patient with Paget's bone disease treated with long-term etidronate. Morphologie, 2012;96(313):40-3. (Elsevier - www.elsevier.com; Morphologie - www.elsevier.com/wps/product/cws_home/709671)
Our news journalists report that additional information may be obtained by contacting E. Hoppe, Service de rhumatologie, CHU, 49933 Angers cedex, France.
Keywords for this news article include: Angers, France, Europe, Osteomalacia, Bone Research, Metabolic Bone Diseases, Musculoskeletal Diseases.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.